Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CALVARUSO, Vincenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.694
EU - Europa 6.077
AS - Asia 6.007
SA - Sud America 937
AF - Africa 167
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 12
Totale 26.919
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.429
SG - Singapore 2.246
RU - Federazione Russa 1.784
IT - Italia 1.487
CN - Cina 1.348
BR - Brasile 751
HK - Hong Kong 581
VN - Vietnam 533
FI - Finlandia 493
BD - Bangladesh 491
DE - Germania 443
PL - Polonia 385
FR - Francia 293
GB - Regno Unito 277
UA - Ucraina 277
IE - Irlanda 204
JP - Giappone 166
IN - India 134
CA - Canada 124
KR - Corea 117
SE - Svezia 97
AR - Argentina 65
MX - Messico 65
NL - Olanda 64
AT - Austria 50
IQ - Iraq 49
RO - Romania 49
TR - Turchia 49
ES - Italia 39
BE - Belgio 36
ZA - Sudafrica 36
PK - Pakistan 33
UZ - Uzbekistan 30
ID - Indonesia 29
VE - Venezuela 29
CI - Costa d'Avorio 28
AU - Australia 21
AZ - Azerbaigian 21
EC - Ecuador 21
EG - Egitto 21
MA - Marocco 21
AE - Emirati Arabi Uniti 20
PY - Paraguay 19
KE - Kenya 18
SA - Arabia Saudita 18
JM - Giamaica 17
JO - Giordania 17
PH - Filippine 16
CO - Colombia 15
IR - Iran 15
MY - Malesia 15
CH - Svizzera 14
LT - Lituania 12
UY - Uruguay 12
DZ - Algeria 10
GR - Grecia 10
PT - Portogallo 10
TW - Taiwan 10
CL - Cile 9
CR - Costa Rica 9
HN - Honduras 9
CZ - Repubblica Ceca 8
DO - Repubblica Dominicana 8
GT - Guatemala 8
IL - Israele 8
NP - Nepal 8
TN - Tunisia 8
BG - Bulgaria 7
BO - Bolivia 7
EU - Europa 7
KZ - Kazakistan 7
OM - Oman 7
KG - Kirghizistan 6
LB - Libano 6
PE - Perù 6
SN - Senegal 6
BY - Bielorussia 5
DK - Danimarca 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
AO - Angola 4
EE - Estonia 4
GE - Georgia 4
KY - Cayman, isole 4
NZ - Nuova Zelanda 4
RS - Serbia 4
SV - El Salvador 4
AL - Albania 3
BH - Bahrain 3
BN - Brunei Darussalam 3
HR - Croazia 3
NG - Nigeria 3
NI - Nicaragua 3
PA - Panama 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
TG - Togo 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
Totale 26.883
Salva come PNG Salva come JPEG
Città #
Ashburn 1.760
Fairfield 1.688
Singapore 1.536
San Jose 851
Woodbridge 806
Houston 705
Seattle 672
Wilmington 638
Chandler 635
Cambridge 584
Hong Kong 557
Ann Arbor 381
Zgierz 341
Moscow 307
Palermo 265
New York 230
Medford 228
Council Bluffs 225
Los Angeles 216
Beijing 204
Dublin 202
Altamura 191
Ho Chi Minh City 182
Helsinki 176
Santa Clara 158
Lauterbourg 156
Tokyo 152
Des Moines 149
Princeton 142
Hanoi 136
Lawrence 134
Nanjing 133
Jacksonville 124
Dallas 112
San Diego 102
Frankfurt am Main 98
The Dalles 95
Boardman 92
Hefei 91
Buffalo 86
Milan 77
Rome 75
London 69
Dearborn 68
São Paulo 68
Phoenix 56
Tulsa 55
Orem 50
Shenyang 50
Nuremberg 49
Ludwigshafen am Rhein 48
Chicago 47
Tianjin 41
Hebei 38
Warsaw 36
Nanchang 35
Changsha 34
Jinan 33
Brussels 31
Columbus 29
San Paolo di Civitate 29
Toronto 29
Abidjan 28
Paris 28
Chennai 27
Jiaxing 27
Lappeenranta 27
Amsterdam 26
Atlanta 25
Redwood City 25
Saint Petersburg 25
Haiphong 24
Da Nang 23
Mumbai 23
Munich 23
Bologna 22
Brooklyn 22
Florence 22
Montreal 22
Ningbo 22
Tashkent 22
Baghdad 20
Falls Church 20
San Francisco 20
Seongnam 20
Baku 19
Denver 19
Johannesburg 18
Zhengzhou 18
Memphis 17
Nairobi 17
Ottawa 17
Salt Lake City 17
Shanghai 17
Vienna 17
Guangzhou 16
Hangzhou 16
Porto Alegre 16
Seoul 16
Stockholm 16
Totale 17.386
Salva come PNG Salva come JPEG
Nome #
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 396
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 329
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 296
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 275
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 272
Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects 269
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 262
Clinical implications of the hyperdynamic syndrome in cirrhosis. 259
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 249
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 249
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 248
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 242
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 241
Baveno VII – Renewing consensus in portal hypertension 236
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 232
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 229
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 229
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 229
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. 224
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 215
A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. 212
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 212
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 211
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients 211
Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis 209
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 207
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients 201
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy 200
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 200
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis 199
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 199
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 197
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 197
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 197
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 196
AISF position paper on liver disease and pregnancy. 196
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease 196
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 196
CLINICAL COURSE OF NIMESULIDE-INDUCED LIVER INJURY 191
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. 191
HCV CLEARANCE AFTER PEG IFN PLUS RBV IMPROVES THE COURSE OF HCV CIRRHOSIS REGARDLESS OF PORTAL HYPERTENSION 189
Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach 189
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? 188
Hepatocellular carcinoma and direct-acting antivirals: A never ending story? 187
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 186
Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study) 186
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 186
A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort 185
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 185
Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy 184
Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis 183
Critically ill patients with cirrhosis and low serum sodium. 183
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis 182
An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers 180
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis 180
A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked to a higher likelihood of hepatocellular carcinoma in patients with HCV cirrhosis 179
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference 178
The impact of sustained virological response on clinical outcome in compensated HCV cirrhosis: a prospective cohort study 176
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 175
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis 174
Impact of Tips Preliver Transplantation for the Outcome Posttransplantation 170
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). 170
Meccanismi immunologici e molecolari del danno epatico da farmaci 169
Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation 168
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy 168
Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model 168
Histological subclassification of cirrhosis 167
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 167
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation 166
Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis 164
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication 163
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. 162
Implication of Normal Liver Enzymes in Liver Disease 161
Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. 160
Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience 160
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 158
TACE versus TAE as therapy for hepatocellular carcinoma. 157
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? 157
The effect of antiviral therapy on clinical outcome of HCV cirrhosis with portal hypertension: a prospective cohort study. 156
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 156
PEG-interferon plus Ribavirin in compensated HCV cirrhosis with portal hypertension: the role of rapid and early virological response in predicting the sustained virological response 155
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 154
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 151
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. 151
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. 151
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis 149
Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to PEG IFN plus RBV 148
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP) 148
PEG_interferon plus Ribavirin in compensated HCV cirrhosis with portal hypertension: the role of rapid and early virological response in predicting the sustained virological response 146
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 146
Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human? 146
Fibrosis in chronic viral hepatitis 145
LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY AND PORTAL HYPERTENSION 145
Predictors of Re‐bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS) 145
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis 145
Computer-Assisted Image Analysis of Liver Collagen: Relationship to Ishak Scoring and Hepatic Venous Pressure Gradient 144
Coagulation and fibrosis in chronic liver disease. 144
RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. 141
Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea 141
Models for non-alcoholic fatty liver disease: a link with vascular risk. 140
Totale 19.056
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.592
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.592
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.752 58 318 149 53 46 67 132 115 213 163 148 290
2022/20232.133 212 488 39 186 247 298 119 148 246 16 73 61
2023/2024922 39 106 82 55 80 226 102 48 18 24 28 114
2024/20252.869 95 244 141 240 84 156 194 144 220 365 359 627
2025/202611.484 679 300 604 909 1.065 1.539 1.439 1.247 1.023 1.094 680 905
2026/2027221 221 0 0 0 0 0 0 0 0 0 0 0
Totale 27.754